Program
selpercatinib
Also written as “Selpercatinib”, “[14C]-Selpercatinib” and “LOXO-292”.
Its studies are mostly in Carcinoma, Non-Small-Cell Lung · Carcinoma, Medullary · Thyroid Neoplasms · Renal Insufficiency, led by Eli Lilly.
Furthest: phase 4, since Sep 11, 202619 company-led studies, 7 open or runningNext primary completion: Oct 2029 (phase 4)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Eli Lilly | 197 open or running | phase 4since Sep 11, 2026 | May 9, 2017 | Oct 2029phase 4 · NCT07822880 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- May 9, 2017First study: phase 2 study in Carcinoma, Non-Small-Cell LungFirst studyNCT03157128 · 857 enrolled · United States, Australia, Canada and more
- Feb 6, 2019Phase 2 study in Carcinoma, MedullaryNCT03899792 · 36 enrolled · United States, Australia, Canada and more
- Dec 9, 20192 phase 3 studiesNCT04194944, NCT04211337
- Feb 20, 2020Phase 2 study in Carcinoma, MedullaryNCT04280081 · 77 enrolled · China
- Mar 2, 2021Phase 1 study in HealthyNCT04782076 · 36 enrolled · United States
- Mar 25, 2021Phase 3 study in Carcinoma, Non-Small-Cell LungNCT04819100 · 152 enrolled · United States, Australia, Austria and more
- Oct 21, 2021Phase 1 study in HealthyNCT05089019 · 224 enrolled · United States
- Nov 25, 2021Phase 1 study in HealthyNCT05136404 · 42 enrolled · United States
- Apr 5, 20223 phase 1 studies in HealthyNCT05324124, NCT05338515, NCT05338502
- Jun 24, 2022Phase 1 study in HealthyNCT05436912 · 36 enrolled · United States
- Jul 19, 20222 phase 1 studiesNCT05468164, NCT05469100
- Nov 21, 20222 phase 1 studies in HealthyNCT05630287, NCT05630274
- Jun 8, 2023Phase 1 study in HealthyNCT05906836 · 28 enrolled · United States
- Sep 11, 2026Phase 4 study in Thyroid NeoplasmsNCT07822880 · 30 planned · India
Ahead
- Oct 2029Primary completion: phase 4 study in Thyroid NeoplasmsNCT07822880
TargetBeta
“An orally bioavailable selective inhibitor of wild-type, mutant and fusion products involving the proto-oncogene receptor tyrosine kinase rearranged during transfection (RET), ”NCIt, by rule
“Tyrosine-protein kinase receptor RET inhibitor; Kinesin-1 heavy chain/ Tyrosine-protein kinase receptor RET inhibitor; Coiled-coil domain-containing protein 6/Tyrosine-protein kinase receptor RET inhibitor”ChEMBL 37, by rule
Other programs on the same three targets
| Program | Company | Furthest phase | Studies |
|---|---|---|---|
| pralsetinibrule | Hoffmann-La Roche | phase 4 | 7 |
Studies
All 19 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07822880Thyroid Neoplasms · India | 4 | Not yet recruiting | Oct 2029 | 30 |
| NCT05906836Healthy · United States | 1 | Completed | Oct 31, 2023 | 28 |
| NCT05630287Healthy · United States | 1 | Completed | Sep 24, 2018 | 12 |
| NCT05630274Healthy · United States | 1 | Completed | Jun 21, 2019 | 32 |
| NCT05469100Renal Insufficiency · United States | 1 | Completed | Aug 7, 2019 | 37 |
| NCT05468164Healthy · United States | 1 | Completed | Sep 13, 2018 | 20 |
| NCT05436912Healthy · United States | 1 | Completed | Oct 4, 2019 | 36 |
| NCT05338515Healthy · United States | 1 | Completed | Mar 12, 2019 | 18 |
| NCT05338502Healthy · United States | 1 | Completed | Sep 3, 2019 | 20 |
| NCT05324124Healthy · Singapore | 1 | Completed | Jun 22, 2022 | 46 |
| NCT05136404Healthy · United States | 1 | Completed | Mar 14, 2022 | 42 |
| NCT05089019Healthy · United States | 1 | Completed | Jul 19, 2022 | 224 |
| NCT04819100Carcinoma, Non-Small-Cell Lung · United States, Australia, Austria and more | 3 | Active, not recruiting | Jan 12, 2026 | 152 |
| NCT04782076Healthy · United States | 1 | Completed | May 17, 2021 | 36 |
| NCT04280081Carcinoma, Medullary · China | 2 | Active, not recruiting | Mar 25, 2021 | 77 |
| NCT04211337Carcinoma, Medullary · United States, Australia, Belgium and more | 3 | Active, not recruiting | May 22, 2023 | 291 |
| NCT04194944Carcinoma, Non-Small-Cell Lung · Argentina, Australia, Belgium and more | 3 | Active, not recruiting | May 1, 2023 | 261 |
| NCT03899792Carcinoma, Medullary · United States, Australia, Canada and more | 2 | Active, not recruiting | Nov 8, 2024 | 36 |
| NCT03157128Carcinoma, Non-Small-Cell Lung · United States, Australia, Canada and more | 2 | Active, not recruiting | Feb 14, 2025 | 857 |
How it is read
Names in the registry
- “Selpercatinib”, 17 entries
- “[14C]-Selpercatinib”, 2 entries
- “LOXO-292”, 1 entry
Conditions, from the studies’ own filings
- Carcinoma, Non-Small-Cell Lung, 3 studies
- Carcinoma, Medullary, 3 studies
- Thyroid Neoplasms, 1 study
- Renal Insufficiency, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.